Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics
Akamis Bio (formerly PsiOxus Therapeutics), a clinical-stage oncology company leveraging its Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer, today announced a $30 million convertible note financing co-led by a group of leading US life science investors. In addition, the company provided a progress update on its clinical pipeline programs, NG-350A and NG-641, while announcing a relaunch of the company as Akamis Bio building upon its ongoing corporate transformation. In conjunction with the corporate name change, the company has launched a new website at www.akamisbio.com.
Akamis Bio, Parker Institute for Cancer Immunotherapy and Cancer Research Institute
Announce Expanded Partnership to Advance Novel Treatments for Pancreatic Cancer
CAMBRIDGE, MA (USA) and OXFORD (UK) – February 16, 2023 – Akamis Bio, a clinical-stage oncology company leveraging its Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer, today announced an expansion of its ongoing partnership with the Parker Institute for Cancer Immunotherapy (PICI) to include a clinical collaboration with the Cancer Research Institute (CRI) that will focus on advancing novel treatments for pancreatic cancer.
Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus Therapeutics for NG-348, an “Armed” Oncolytic Virus to Address Solid Tumors
Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an agreement granting Bristol-Myers Squibb exclusive worldwide rights to NG-348, a pre-clinical stage, “armed” oncolytic virus with the goal of addressing solid tumors.
EMA grants positive opinion for orphan drug status for ovarian cancer oncolytic vaccine
PsiOxus Therapeutics Ltd. (PsiOxus), an Oxford, UK based biotechnology company developing innovative new treatments for cancer, has been granted a positive opinion from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) for an orphan medicinal product designation of its oncolytic vaccine, enadenotucirev (previously known as ColoAd1) for the treatment of platinum-resistant epithelial ovarian cancer.
PsiOxus Initiates Combination Study of Merck’s Keytruda with Oncolytic Virus Enadenotucirev
PsiOxus Therapeutics Ltd. (PsiOxus), the immuno- oncology company, has initiated a study to assess the safety and efficacy of a therapy combining Merck’s Keytruda® (pembrolizumab) and PsiOxus’ lead product, enadenotucirev, to treat patients with carcinomas.
PsiOxus Therapeutics Announce Executive Team Reorganization with Two New C Level Appointments in the US
PsiOxus Therapeutics, Ltd. (PsiOxus) today announced the appointment of Dr Charles “Charlie” Morris as Chief Development Officer and Karen LaRochelle as Chief Business Officer, both of whom will be based in the United States.
PsiOxus Therapeutics Announces Clinical Trial with Third Cancer Gene Therapy Treatment and Appointment of New Chief Medical Officer.
PsiOxus Therapeutics, Ltd. (PsiOxus), the gene therapy for cancer company, today announced that it has started a clinical trial with NG-641, a four transgene tumor-microenvironment modifying cancer gene therapy.